StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note published on Wednesday. The firm issued a sell rating on the medical research company’s stock.
Organovo Stock Up 1.2 %
Shares of NASDAQ:ONVO opened at $0.47 on Wednesday. The firm has a 50-day simple moving average of $0.54 and a 200 day simple moving average of $0.79. Organovo has a fifty-two week low of $0.43 and a fifty-two week high of $2.05. The company has a market cap of $6.70 million, a PE ratio of -0.29 and a beta of 0.61.
Organovo (NASDAQ:ONVO – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The medical research company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.15. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.03 million. As a group, research analysts forecast that Organovo will post -0.96 EPS for the current fiscal year.
Institutional Trading of Organovo
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Read More
- Five stocks we like better than Organovo
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- What is Put Option Volume?
- MarketBeat Week in Review – 9/30 – 10/4
- How to Find Undervalued Stocks
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.